Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Short-term Investments (2016 - 2025)

Karyopharm Therapeutics' Short-term Investments history spans 12 years, with the latest figure at $3.2 million for Q4 2025.

  • For Q4 2025, Short-term Investments fell 93.07% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $3.2 million, down 93.07%, while the annual FY2025 figure was $3.2 million, 93.07% down from the prior year.
  • Short-term Investments reached $3.2 million in Q4 2025 per KPTI's latest filing, down from $8.2 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $176.3 million in Q1 2023 to a low of $3.2 million in Q4 2025.
  • Average Short-term Investments over 5 years is $84.0 million, with a median of $72.2 million recorded in 2022.
  • Peak YoY movement for Short-term Investments: soared 274.2% in 2022, then plummeted 93.07% in 2025.
  • A 5-year view of Short-term Investments shows it stood at $38.2 million in 2021, then skyrocketed by 274.2% to $142.8 million in 2022, then decreased by 2.5% to $139.2 million in 2023, then tumbled by 66.79% to $46.2 million in 2024, then tumbled by 93.07% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Short-term Investments are $3.2 million (Q4 2025), $8.2 million (Q3 2025), and $13.0 million (Q2 2025).